@article{ee9b4c38d30c4dcb93116134c2793dea,
title = "Erratum: Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib (Communications biology (2023) 6 1 (509))",
author = "Meraz, {Ismail M.} and Mourad Majidi and Bingliang Fang and Feng Meng and Lihui Gao and Shao, {Ru Ping} and Renduo Song and Feng Li and Yonathan Lissanu and Huiqin Chen and Ha, {Min Jin} and Qi Wang and Jing Wang and Elizabeth Shpall and Jung, {Sung Yun} and Franziska Haderk and Philippe Gui and Riess, {Jonathan Wesley} and Victor Olivas and Bivona, {Trever G.} and Roth, {Jack A.}",
note = "Funding Information: {\textquoteleft}J.A.R. reports receiving a commercial research grant from The University of Texas MD Anderson Cancer Center, sponsored research agreement from Genprex, Inc, has ownership interest (including stock, patents, etc.) in Genprex, Inc., and is a consultant/advisory boardmember for Genprex, Inc. T.G.B. is an advisor to Array/Pfizer, Revolution Medicines, Springworks, Jazz Pharmaceuticals, Relay Therapeutics, Rain Therapeutics, Engine Biosciences, and receives research funding from Novartis, Strategia, Kinnate, and Revolution Medicines. J.W.R. is an advisor to Blueprint, Beigene, Daiichi Sankyo, EMD Serono, Janssen, Turning Point, Regeneron, Sanofi Aventis and a consultant to Blueprint, Novartis, Boehringer Ingelheim. He also receives research funding from Merck, Novartis, Spectrum, Revolution Medicine, AstraZeneca.The other authors disclosed no potential conflicts of interest or competing interests.{\textquoteright} ",
year = "2023",
month = jun,
day = "6",
doi = "10.1038/s42003-023-04979-9",
language = "English (US)",
volume = "6",
pages = "608",
journal = "Communications Biology",
issn = "2399-3642",
publisher = "Springer Nature",
number = "1",
}